{"analyses":[{"ciLowerLimit":"0.34","ciPctValue":"95","ciUpperLimit":"0.62","estimateComment":"The estimated value is the hazard ratio comparing pazopanib to placebo.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":".0000001","pValueComment":"stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.46","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.4","upperLimit":"12.9","value":"9.2"},{"groupId":"OG001","lowerLimit":"2.8","upperLimit":"5.6","value":"4.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is defined as the interval between the date of randomization and the earliest date of disease progression or death due to any cause. Assessments of progression and non-progression were made by an independent imaging review committee (IRC) for the primary analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pazopanib 800 mg (tablets) administered orally once a day","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Matching Placebo administered once a day","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Population: all randomized participants","reportingStatus":"POSTED","timeFrame":"Randomization until progression (up to 2 years)","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"months"}